{
  "entities": {
    "activities": {
      "334becbf-9c9d-47a3-8010-75680bb5d155": "7-Field CFP",
      "ae4c35b9-1ce5-4153-ad47-871b1e547f58": "Adverse Events",
      "745abab8-9302-4471-842b-81b577da2791": "BCVA",
      "5eb5a0e9-90a4-4403-b1c4-b31424f6c972": "Best Corrected Visual Acuity",
      "09396e73-325d-4636-8ab6-1d74cc882b08": "Brolucizumab 6 mg injection",
      "e4682b93-7aad-4028-9172-3c8ec8d67d57": "Color fundus photography",
      "c2b5de3e-e797-4971-b8d6-ff37da1c7fd6": "Demographics",
      "c49cc08c-66cd-446a-9c2f-60a58b4f4d41": "FA",
      "757a92f8-3ac9-4107-a08c-3f5adbb67f02": "Fluorescein angiography",
      "005f26dd-9f9c-4d18-bee1-1fbd9654a87c": "IOP",
      "90846288-0c7f-47cc-9aa2-11044f4fab6f": "Inclusion / Exclusion Criteria",
      "f1f8e989-85e3-45fb-b3ff-7f4eee08128a": "Informed Consent",
      "45538ed8-8bfd-4c7e-b9a5-fa5761f442ef": "Intraocular pressure measurement",
      "2954a788-dc69-4a9b-af18-09681ef688f8": "Intravitreal injection",
      "6c707f95-3624-4188-bee2-7c7b71267d49": "Laboratory evaluation",
      "c5539d18-a488-4d18-af8c-e8f39bb51dd0": "Medical History",
      "494bbdcc-645c-46ed-a5dc-610fa7ec4bfe": "PRP treatment",
      "5ce8ff39-dd14-463d-8294-8e6c239e4918": "Panretinal photocoagulation",
      "12d423e8-5656-4639-9207-79c0eabc7643": "Prior / Concomitant Medications",
      "93aa0989-4d8e-4ba5-8d89-3a04a50dc835": "Randomization",
      "0ddf2abb-a635-4f7f-b2c1-dce8fc0c1435": "SD-OCT",
      "45209d80-6822-43ea-b1dd-a997b1d17b72": "Spectral domain optical coherence tomography",
      "55844c94-c5c6-4bab-9913-d20555b06af2": "Vital Signs",
      "f7b19f4d-5a5b-401a-948d-41fa97106392": "Vitrectomy"
    },
    "plannedTimepoints": {},
    "encounters": {
      "a1d46d81-5028-4e82-9f70-7a42fc3bbe63": "Screening (Day -21 to Day -1)",
      "e06c41f4-d1f7-4190-af82-aac8391e79c8": "Baseline (Day 1)",
      "cc879727-1a3d-4005-9399-063c443ff915": "Week 6",
      "499ea356-9eaf-4db0-8d44-513b7e7f2b97": "Week 12",
      "2003dff8-84b2-4ca2-8370-a083daa38411": "Week 18",
      "dbbb5aeb-d13b-42ff-a206-481a502dab9e": "Week 24",
      "d354cc10-7432-4102-a730-8f7ce921db2d": "Week 30",
      "a65221d6-6e87-4bc0-9ca9-588f50162e0b": "Week 36",
      "ea13b782-1830-43ff-86a5-aad732e3c001": "Week 42",
      "41081156-c822-4015-aee0-9d398f60aa95": "Week 48",
      "ac5e2260-4eb2-4b31-bb25-9c42d976ceaf": "Week 54 (Primary Endpoint)",
      "3a3a8f0a-92b8-4218-9ad7-7443f669117a": "Week 60",
      "8760155e-15ac-4311-affa-ce23c990f890": "Week 66",
      "2edd31c0-5b71-4f1d-89a4-f61afd84a0a1": "Week 72",
      "16d4f35f-86a2-4ed0-a484-4efe366908fd": "Week 78",
      "d3e5614a-3b3e-4f9b-9259-0fd335f35984": "Week 84",
      "dd9e48a0-1ceb-485a-98bf-18e678d5959c": "Week 90 (End of Treatment)",
      "1432f56c-2808-40a5-a44a-1d0d329fe2bf": "Week 96 (End of Study)"
    },
    "epochs": {
      "70062ad0-6a81-40ac-8e76-0f69590ad06b": "Screening period",
      "74dfbcb2-2302-4e4f-9aa5-edb420a117b4": "Single-Masked Treatment Period",
      "4b838010-a86a-44d4-afdb-1e76dcc7e86c": "Follow-up period"
    },
    "activityGroups": {}
  },
  "cells": {
    "f1f8e989-85e3-45fb-b3ff-7f4eee08128a|a1d46d81-5028-4e82-9f70-7a42fc3bbe63": "both",
    "90846288-0c7f-47cc-9aa2-11044f4fab6f|a1d46d81-5028-4e82-9f70-7a42fc3bbe63": "both",
    "90846288-0c7f-47cc-9aa2-11044f4fab6f|e06c41f4-d1f7-4190-af82-aac8391e79c8": "both",
    "c2b5de3e-e797-4971-b8d6-ff37da1c7fd6|a1d46d81-5028-4e82-9f70-7a42fc3bbe63": "both",
    "c5539d18-a488-4d18-af8c-e8f39bb51dd0|a1d46d81-5028-4e82-9f70-7a42fc3bbe63": "both",
    "12d423e8-5656-4639-9207-79c0eabc7643|a1d46d81-5028-4e82-9f70-7a42fc3bbe63": "both",
    "12d423e8-5656-4639-9207-79c0eabc7643|e06c41f4-d1f7-4190-af82-aac8391e79c8": "both",
    "93aa0989-4d8e-4ba5-8d89-3a04a50dc835|e06c41f4-d1f7-4190-af82-aac8391e79c8": "both",
    "55844c94-c5c6-4bab-9913-d20555b06af2|a1d46d81-5028-4e82-9f70-7a42fc3bbe63": "both",
    "55844c94-c5c6-4bab-9913-d20555b06af2|e06c41f4-d1f7-4190-af82-aac8391e79c8": "both",
    "005f26dd-9f9c-4d18-bee1-1fbd9654a87c|a1d46d81-5028-4e82-9f70-7a42fc3bbe63": "both",
    "005f26dd-9f9c-4d18-bee1-1fbd9654a87c|e06c41f4-d1f7-4190-af82-aac8391e79c8": "both",
    "745abab8-9302-4471-842b-81b577da2791|a1d46d81-5028-4e82-9f70-7a42fc3bbe63": "both",
    "745abab8-9302-4471-842b-81b577da2791|e06c41f4-d1f7-4190-af82-aac8391e79c8": "both",
    "745abab8-9302-4471-842b-81b577da2791|ac5e2260-4eb2-4b31-bb25-9c42d976ceaf": "both",
    "745abab8-9302-4471-842b-81b577da2791|1432f56c-2808-40a5-a44a-1d0d329fe2bf": "both",
    "c49cc08c-66cd-446a-9c2f-60a58b4f4d41|a1d46d81-5028-4e82-9f70-7a42fc3bbe63": "both",
    "09396e73-325d-4636-8ab6-1d74cc882b08|e06c41f4-d1f7-4190-af82-aac8391e79c8": "both",
    "09396e73-325d-4636-8ab6-1d74cc882b08|cc879727-1a3d-4005-9399-063c443ff915": "both",
    "09396e73-325d-4636-8ab6-1d74cc882b08|499ea356-9eaf-4db0-8d44-513b7e7f2b97": "both",
    "09396e73-325d-4636-8ab6-1d74cc882b08|dd9e48a0-1ceb-485a-98bf-18e678d5959c": "both",
    "494bbdcc-645c-46ed-a5dc-610fa7ec4bfe|e06c41f4-d1f7-4190-af82-aac8391e79c8": "both",
    "494bbdcc-645c-46ed-a5dc-610fa7ec4bfe|499ea356-9eaf-4db0-8d44-513b7e7f2b97": "both"
  },
  "cellFootnotes": {},
  "metadata": {
    "model": "gemini-3-flash-preview",
    "extraction_type": "text"
  }
}